

Date: 26th October 2026

To,

**National Stock Exchange of India
Limited Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (E),
Mumbai – 400051**

**BSE Limited
Phiroze Jeejeebhoy Towers Dalal
Street, Mumbai – 400001**

Scrip Symbol- SUDEEPPHRM

Scrip Code: 544619

**Sub: FDA approval for the new pharma greenfield manufacturing facility at 179
Nandesari, Gujarat.**

Dear Sir/Madam,

This is to inform to the Exchange that, the Company has received FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat.

Press release is enclosed herewith.

This is for your information and records.

Sincerely,

For Sudeep Pharma Limited

**DIMPLE
ASHWINBHAI
MEHTA**

Digitally signed by DIMPLE
ASHWINBHAI MEHTA
DN: cn=DIMPLE ASHWINBHAI
MEHTA, c=IN, st=Gujarat, o=Personal,
title=8748,
serialNumber=be901a7b4cfd5ff4b6e33
10581e678592e8fca3536566c4a365b
a53eccbf1a6
Date: 2026.10.26 12:24:39 +05'30'

**Dimple Mehta
Company Secretary & Compliance Officer
M. No: F13184**

ENCL: A/a

CIN: L24231GJ1989PLC013141

Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India.

Phone No.: +91 265 2840656, 7624095107

Corporate Office: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021,
Gujarat, India Website: www.sudeeppharma.com, Email ID: mail@sudeepgroup.com



Sudeep Pharma Limited

FDA Approval Enables Commencement of Operations at New Pharma Greenfield Facility at 179 Nandesari, Gujarat

- Received FDA approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, authorising the commencement of manufacturing operations at the site.
- The facility has an annual installed capacity of 51,200 MT, strengthening manufacturing capabilities across Pharma, Food & Nutrition and Specialty Ingredients.
- Approval allows the Company to bring the new capacity on stream and serve growing demand from pharmaceutical, food and nutrition customers in domestic and international markets.

Vadodara, October 26th, 2026: Sudeep Pharma Limited (NSE: SUDEEPPHRM, BSE: 544619), a leading manufacturer of pharmaceutical excipients, food and nutrition ingredients and specialty mineral-based solutions, today announced that its new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, has received approval from the Gujarat Food and Drug Control Administration (FDA), authorising the Company to commence manufacturing operations at the site.

The approval marks a significant milestone in the Company's growth journey and confirms that the facility's manufacturing systems, quality controls and compliance framework meet the requirements for commencing manufacturing operations. It reinforces the Company's commitment to strengthening manufacturing capabilities, quality standards and regulatory compliance. With an installed annual capacity of 51,200 MT, the facility represents an important addition to the Company's manufacturing infrastructure and will support its growing business requirements across domestic and international markets. Commercial supplies from this facility are expected to commence in H2 FY27, following the completion of customer qualification processes.

Approximately 60% of the facility's capacity is allocated to the Company's existing Pharma, Food & Nutrition portfolio, while the remaining capacity will cater to newer product categories, including phosphates, glycines, gluconates and citrates.

The facility will also provide dedicated capacity for higher-value ingredients, reinforcing the Company's focus on portfolio diversification and strengthening its presence in regulated markets. Importantly, the additional capacity will enable the Company to manufacture new-age, high-value molecules such as bisglycines, for which capacity at the existing mother plant was constrained. This will allow the Company to scale up production, cater to growing customer requirements and capitalise on emerging opportunities in specialised ingredients.

Commenting on the development, Mr. Sujit Bhayani, Managing Director, Sudeep Pharma Limited, said:

"The FDA approval for our 179 Nandesari greenfield facility marks an important milestone in our growth journey, enabling us to commence manufacturing operations and unlock significant additional capacity. It strengthens our ability to serve a wider customer base across pharmaceutical, food and nutrition segments in India and international markets. With the approval in place, we can now accelerate customer qualification processes and audits at the facility, facilitating the onboarding of both new and existing customers.

The facility also provides us with the flexibility to expand our presence across existing and newer product categories, including high-value, specialised ingredients such as bisglycinates. This will enable us to address evolving customer requirements, scale up our specialised ingredients portfolio and pursue larger opportunities in international markets. We believe this investment will serve as an important growth driver as we progress into the next phase of our journey."

About Sudeep Pharma Limited

Sudeep Pharma Limited is a leading manufacturer of pharmaceutical excipients, food and nutrition ingredients and specialty mineral-based solutions, serving customers across India and international markets. With a strong foundation in mineral chemistry, manufacturing expertise and quality control, the Company offers a diversified portfolio of ingredients catering to pharmaceutical, food, nutrition and other specialised applications. The Company continues to expand its manufacturing capabilities, product portfolio and global presence, with a focus on innovation, value-added products and emerging growth opportunities, including battery materials through its subsidiary, Sudeep Advanced Materials.

For more information, please contact:

<u>Company Details</u>	<u>Investor Relations Advisors</u>
<u>Sudeep Pharma Ltd.</u>  CIN: L24231GJ1989PLC013141 Ms. Dimple Mehta – Company Secretary Email Id – cs.sudeep@sudeepgroup.com Telephone: +91 265 284 0656/329 1354 www.sudeeppharma.com	<u>Strategic Growth Advisors Pvt. Ltd.</u>  CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email Id - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sudeep Pharma Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.